Cat. No.: HY-128139

2'-C-Methylguanosine

(Synonyms: 2'-C-beta-Methylguanosine)

Customer Review

Based on 1 Customer Validation

2'-C-Methylguanosine (2'-C-beta-Methylguanosine) is a guanosine analogue. Some guanosine analogs have immunostimulatory activity. In some animal models, they also induce type I interferons, producing antiviral effects. Studies have shown that the functional activity of guanosine analogs is dependent on the activation of Toll-like receptor 7 (TLR7).

For research use only. We do not sell to patients.

Purity: 99.70%
CAS No.: 374750-30-8
Formula: C₁₁H₁₅N₅O₅
Molecular Weight:297.27

Storage:

Powder -20°C, 3 years ; In solvent -80°C, 6 months , -20°C, 1 month

2'-C-Methylguanosine Chemical Structure

CAS No.: 374750-30-8

Size

Price

Stock

Quantity

Amount: USD 0.00

* Please select Quantity before adding items.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- Description
- Cellular Effect
Chemical Information
Purity & Documentation
References
Calculators
Help & FAQs
Bioz

Biological Activity

Description

Cellular Effect

Cell Line	Type	Value	Description	References
BHK-21	CC₅₀	>10 μM Compound: 2'-C-methyl-guanosine	Cytotoxicity against BHK21 cells by MTT assay Cytotoxicity against BHK21 cells by MTT assay	[PMID: 22513121]
BHK-21	CC₅₀	>10 μM Compound: 2'-MeGua	Cytotoxicity against mock-infected BHK21 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against mock-infected BHK21 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 27161176]
BHK-21	CC₅₀	>10 μM Compound: 2'-MeGuo	Cytotoxicity against BHK21 cells after 48 to 96 hrs by MTT assay Cytotoxicity against BHK21 cells after 48 to 96 hrs by MTT assay	[PMID: 22047799]
BHK-21	CC₅₀	>100 μM Compound: 2'-C-methyl-guanosine	Cytotoxicity against golden hamster BHK21 cells assessed as reduction in cell viability after 48 to 96 hrs by MTT assay Cytotoxicity against golden hamster BHK21 cells assessed as reduction in cell viability after 48 to 96 hrs by MTT assay	[PMID: 29339251]
BHK-21	CC₅₀	>100 μM Compound: Met-Gua	Cytotoxicity against mock-infected hamster BHK21 cells assessed as reduction in proliferation after 72 hrs by MTT method Cytotoxicity against mock-infected hamster BHK21 cells assessed as reduction in proliferation after 72 hrs by MTT method	[PMID: 25014745]
BHK-21	CC₅₀	1.1 μM Compound: Met-Gua	Cytotoxicity against BHK21 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against BHK21 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 26479028]
BHK-21	CC₅₀	90 μM Compound: NM 108	Cytotoxicity against hamster BHK21 cells assessed as reduction in cell viability after 48 to 96 hrs by MTT assay Cytotoxicity against hamster BHK21 cells assessed as reduction in cell viability after 48 to 96 hrs by MTT assay	[PMID: 19482481]
BHK-21	CC₅₀	90 μM Compound: NM 108	Cytotoxicity against mock-infected BHK21 cells after 48 to 96 hrs by MTT assay Cytotoxicity against mock-infected BHK21 cells after 48 to 96 hrs by MTT assay	[PMID: 25082514]
BHK-21	EC₅₀	>100 μM Compound: Met-Gua	Antiviral activity against YFV 17-D vaccine (Stamaril Pasteur J07B01) infected in BHK21 cells assessed as protection against virus-induced cytopathic effect after 3 or 4 days by MTT assay Antiviral activity against YFV 17-D vaccine (Stamaril Pasteur J07B01) infected in BHK21 cells assessed as protection against virus-induced cytopathic effect after 3 or 4 days by MTT assay	[PMID: 26479028]
BHK-21	EC₅₀	>100 μM Compound: NM 108	Antiviral activity against Yellow fever virus infected in BHK21 cells assessed as inhibition of virus-induced cytopathogenicity after 3 to 4 days by MTT assay Antiviral activity against Yellow fever virus infected in BHK21 cells assessed as inhibition of virus-induced cytopathogenicity after 3 to 4 days by MTT assay	[PMID: 25082514]
BHK-21	EC₅₀	0.7 μM Compound: NM108	Antiviral activity against WNV infected in BHK-21 cells assessed as inhibition of virus-induced cytopathogenicity after 3 to 4 days by MTT assay Antiviral activity against WNV infected in BHK-21 cells assessed as inhibition of virus-induced cytopathogenicity after 3 to 4 days by MTT assay	[PMID: 26443549]
BHK-21	EC₅₀	1 μM Compound: NM-108	Antiviral activity against YFV infected in BHK21 cells assessed as protection against virus-induced cytopathogenicity after 4 days by MTT assay Antiviral activity against YFV infected in BHK21 cells assessed as protection against virus-induced cytopathogenicity after 4 days by MTT assay	[PMID: 18760610]
BHK-21	EC₅₀	1.2 μM Compound: NM108	Antiviral activity against DENV-2 infected in BHK-21 cells assessed as inhibition of virus-induced cytopathogenicity after 3 to 4 days by MTT assay Antiviral activity against DENV-2 infected in BHK-21 cells assessed as inhibition of virus-induced cytopathogenicity after 3 to 4 days by MTT assay	[PMID: 26443549]
BHK-21	EC₅₀	1.5 μM Compound: NM108	Antiviral activity against YFV infected in BHK-21 cells assessed as inhibition of virus-induced cytopathogenicity after 3 to 4 days by MTT assay Antiviral activity against YFV infected in BHK-21 cells assessed as inhibition of virus-induced cytopathogenicity after 3 to 4 days by MTT assay	[PMID: 26443549]
BHK-21	EC₅₀	1.8 μM Compound: NM 108	Antiviral activity against Yellow fever virus infected in BHK-21 cells assessed as inhibition of virus-induced cytopathicity after 3 to 4 days by MTT assay Antiviral activity against Yellow fever virus infected in BHK-21 cells assessed as inhibition of virus-induced cytopathicity after 3 to 4 days by MTT assay	[PMID: 19482481]
BHK-21	EC₅₀	1.9 μM Compound: 2'-C-methyl-guanosine	Antiviral activity against Yellow fever virus 17D infected in BHK21 cells assessed as inhibition of virus-induced cytopathogenicity after 3 to 4 days by MTT assay Antiviral activity against Yellow fever virus 17D infected in BHK21 cells assessed as inhibition of virus-induced cytopathogenicity after 3 to 4 days by MTT assay	[PMID: 22513121]
BHK-21	EC₅₀	1.9 μM Compound: 2'-MeGua	Antiviral activity against Yellow fever virus 17D infected in BHK21 cells assessed as inhibition of virus induced cytopathogenicity after 3 to 4 days by MTT assay Antiviral activity against Yellow fever virus 17D infected in BHK21 cells assessed as inhibition of virus induced cytopathogenicity after 3 to 4 days by MTT assay	[PMID: 27161176]
BHK-21	EC₅₀	1.9 μM Compound: 2'-MeGuo	Antiviral activity against Yellow fever virus 17D Stamaril Pasteur J07B01 infected in hamster BHK21 cells assessed as inhibition of virus-induced cytopathogenicity after 3 to 4 days by MTT assay Antiviral activity against Yellow fever virus 17D Stamaril Pasteur J07B01 infected in hamster BHK21 cells assessed as inhibition of virus-induced cytopathogenicity after 3 to 4 days by MTT assay	[PMID: 22047799]
BHK-21	EC₅₀	1.9 μM Compound: Met-Gua	Antiviral activity against Yellow fever virus 17D Stamaril Pasteur J07B01 infected in BHK21 cells assessed as protection from virus-induced cytopathogenicity after 3 to 4 days by MTT method Antiviral activity against Yellow fever virus 17D Stamaril Pasteur J07B01 infected in BHK21 cells assessed as protection from virus-induced cytopathogenicity after 3 to 4 days by MTT method	[PMID: 25014745]
BHK-21	EC₅₀	1.9 μM Compound: Met-Gua	Antiviral activity against Reovirus 1 ATCC VR- 214 infected in BHK21 cells assessed as protection against virus-induced cytopathic effect after 3 or 4 days by MTT assay Antiviral activity against Reovirus 1 ATCC VR- 214 infected in BHK21 cells assessed as protection against virus-induced cytopathic effect after 3 or 4 days by MTT assay	[PMID: 26479028]
BHK-21	EC₅₀	2.4 μM Compound: NM 108	Antiviral activity against Reovirus-1 infected in BHK-21 cells assessed as inhibition of virus-induced cytopathicity after 3 to 4 days by MTT assay Antiviral activity against Reovirus-1 infected in BHK-21 cells assessed as inhibition of virus-induced cytopathicity after 3 to 4 days by MTT assay	[PMID: 19482481]
BHK-21	EC₅₀	2.4 μM Compound: NM 108	Antiviral activity against Reovirus 1 3651 infected in BHK21 cells assessed as protection from virus-induced cytopathogenicity after 3 to 4 days by MTT method Antiviral activity against Reovirus 1 3651 infected in BHK21 cells assessed as protection from virus-induced cytopathogenicity after 3 to 4 days by MTT method	[PMID: 20359898]
BHK-21	EC₅₀	2.4 μM Compound: NM 108	Antiviral activity against Reovirus type-1 infected in BHK21 cells assessed as inhibition of virus-induced cytopathogenicity after 3 to 4 days by MTT assay Antiviral activity against Reovirus type-1 infected in BHK21 cells assessed as inhibition of virus-induced cytopathogenicity after 3 to 4 days by MTT assay	[PMID: 25082514]
BHK-21	EC₅₀	2.4 μM Compound: NM108	Antiviral activity against Reo-1 virus infected in BHK-21 cells assessed as inhibition of virus-induced cytopathogenicity after 3 to 4 days by MTT assay Antiviral activity against Reo-1 virus infected in BHK-21 cells assessed as inhibition of virus-induced cytopathogenicity after 3 to 4 days by MTT assay	[PMID: 26443549]
BHK-21	EC₅₀	2.5 μM Compound: NM108	Antiviral activity against Yellow fever virus infected Syrian hamster BHK-21 cells assessed as protection against virus-induced cytopathogenicity treated 1 hr after viral infection measured after 3-4 days by MTT method Antiviral activity against Yellow fever virus infected Syrian hamster BHK-21 cells assessed as protection against virus-induced cytopathogenicity treated 1 hr after viral infection measured after 3-4 days by MTT method	10.1007/s00044-012-0342-1
CCRF-CEM	CC₅₀	>100 μM Compound: 8, 2'-C-MeG	Cytotoxicity against human CEM cells Cytotoxicity against human CEM cells	[PMID: 19433343]
Huh-5-2	CC₅₀	>50 μM Compound: 2	Cytotoxicity against human Huh5-2 cells Cytotoxicity against human Huh5-2 cells	[PMID: 19523820]
Huh-5-2	EC₅₀	10.1 μM Compound: 2	Antiviral activity against HCV assessed as inhibition of viral replicon replication in human Huh5-2 cells Antiviral activity against HCV assessed as inhibition of viral replicon replication in human Huh5-2 cells	[PMID: 19523820]
Huh-7	CC₅₀	>100 μM Compound: 1	Cytotoxicity against Huh7 cells by MTS assay Cytotoxicity against Huh7 cells by MTS assay	[PMID: 16368235]
Huh-7	CC₅₀	>100 μM Compound: 1c	Cytotoxicity against human HuH7 cells after 72 hrs by celltiter-glo assay Cytotoxicity against human HuH7 cells after 72 hrs by celltiter-glo assay	[PMID: 20527890]
Huh-7	CC₅₀	>100 μM Compound: 4	Cytotoxicity against human HuH7 cells after 3 days Cytotoxicity against human HuH7 cells after 3 days	[PMID: 22039920]
Huh-7	CC₅₀	>89 μM Compound: 2'-C-Me G	Cytotoxicity against human HuH7 cells after 24 hrs by MTS assay Cytotoxicity against human HuH7 cells after 24 hrs by MTS assay	[PMID: 22578461]
Huh-7	EC₅₀	2.2 μM Compound: 4	Antiviral activity against Hepatitis C virus subtype 1b Con1 infected in human Huh7 cells assessed as inhibition of HCV replicon-encoded Renilla luciferase reporter activity after 72 hrs by HCV replicon assay Antiviral activity against Hepatitis C virus subtype 1b Con1 infected in human Huh7 cells assessed as inhibition of HCV replicon-encoded Renilla luciferase reporter activity after 72 hrs by HCV replicon assay	[PMID: 22039920]
Huh-7	EC₅₀	2.3 μM Compound: 8, 2'-C-MeG	Antiviral activity against HCV in human Huh7 cells by RNA replicon assay Antiviral activity against HCV in human Huh7 cells by RNA replicon assay	[PMID: 19433343]
Huh-7	EC₅₀	3.25 μM Compound: 2'-C-Me G	Antiviral activity against HCV genotype 1b infected in human HuH7 cells assessed as cytoprotection after 24 hrs Antiviral activity against HCV genotype 1b infected in human HuH7 cells assessed as cytoprotection after 24 hrs	[PMID: 22578461]
Huh-7	EC₅₀	3.5 μM Compound: 1c	Antiviral activity against HCV1b infected in human HuH7 cells assessed as inhibition of viral replication after 48 hrs by luciferase reporter gene assay Antiviral activity against HCV1b infected in human HuH7 cells assessed as inhibition of viral replication after 48 hrs by luciferase reporter gene assay	[PMID: 20527890]
MDCK	EC₅₀	1.7 μM Compound: NM-108	Antiviral activity against BVDV infected in MDCK cells assessed as inhibition of virus-induced cytopathogenicity by MTT assay Antiviral activity against BVDV infected in MDCK cells assessed as inhibition of virus-induced cytopathogenicity by MTT assay	[PMID: 20638852]
MT4	CC₅₀	>100 μM Compound: NM 108	Cytotoxicity against human MT4 cells after 96 hrs by MTT method Cytotoxicity against human MT4 cells after 96 hrs by MTT method	[PMID: 18054491]
MT4	CC₅₀	>100 μM Compound: NM 108	Cytotoxicity against human MT4 cells after 96 hrs by MTT assay Cytotoxicity against human MT4 cells after 96 hrs by MTT assay	[PMID: 19482481]
MT4	CC₅₀	>100 μM Compound: NM 108	Cytotoxicity against human MT4 cells after 96 hrs by MTT assay Cytotoxicity against human MT4 cells after 96 hrs by MTT assay	[PMID: 20359898]
MT4	CC₅₀	>100 μM Compound: NM 108	Cytotoxicity against mock-infected human MT4 cells after 96 hrs by MTT assay Cytotoxicity against mock-infected human MT4 cells after 96 hrs by MTT assay	[PMID: 25082514]
MT4	CC₅₀	>100 μM Compound: NM108	Cytotoxicity against human MT4 cells assessed as cell viability after 96 hrs by MTT assay Cytotoxicity against human MT4 cells assessed as cell viability after 96 hrs by MTT assay	[PMID: 26443549]
MT4	CC₅₀	>100 μM Compound: NM-108	Cytotoxicity against mock-infected human MT4 cells assessed as reduction in cell viability after 96 hrs by MTT assay Cytotoxicity against mock-infected human MT4 cells assessed as reduction in cell viability after 96 hrs by MTT assay	[PMID: 18760610]
PBMC	CC₅₀	>100 μM Compound: 8, 2'-C-MeG	Cytotoxicity against human PBMC cells Cytotoxicity against human PBMC cells	[PMID: 19433343]
Vero	CC₅₀	>100 μM Compound: NM 108	Cytotoxicity against african green monkey Vero 76 cells by crystal violet staining Cytotoxicity against african green monkey Vero 76 cells by crystal violet staining	[PMID: 19482481]
Vero	CC₅₀	>100 μM Compound: NM-108	Cytotoxicity against mock-infected african green monkey Vero76 cells assessed as reduction in cell viability after 96 hrs by MTT assay Cytotoxicity against mock-infected african green monkey Vero76 cells assessed as reduction in cell viability after 96 hrs by MTT assay	[PMID: 18760610]
Vero	CC₅₀	>100 μM Compound: 8, 2'-C-MeG	Cytotoxicity against african green monkey Vero cells Cytotoxicity against african green monkey Vero cells	[PMID: 19433343]
Vero	CC₅₀	>100 μM Compound: NM 108	Cytotoxicity against african green monkey Vero cells Cytotoxicity against african green monkey Vero cells	[PMID: 20359898]
Vero	CC₅₀	>200 μM Compound: 1; 2'-C-beta-Me-G	Cytotoxicity against African green monkey Vero cells assessed as decrease in cell viability after 72 hrs by neutral red dye uptake assay Cytotoxicity against African green monkey Vero cells assessed as decrease in cell viability after 72 hrs by neutral red dye uptake assay	[PMID: 28947944]
Vero	EC₅₀	>100 μM Compound: NM 108	Antiviral activity against HSV1 KOS infected in african green monkey Vero cells after 3 days by plaque reduction assay Antiviral activity against HSV1 KOS infected in african green monkey Vero cells after 3 days by plaque reduction assay	[PMID: 20359898]
Vero	EC₅₀	>100 μM Compound: NM 108	Antiviral activity against Polio virus type1 Sabin strain Chat infected in african green monkey Vero cells after 2 days by plaque reduction assay Antiviral activity against Polio virus type1 Sabin strain Chat infected in african green monkey Vero cells after 2 days by plaque reduction assay	[PMID: 20359898]
Vero	EC₅₀	>100 μM Compound: NM 108	Antiviral activity against RSV A2 infected in african green monkey Vero cells after 5 days by plaque reduction assay Antiviral activity against RSV A2 infected in african green monkey Vero cells after 5 days by plaque reduction assay	[PMID: 20359898]
Vero	EC₅₀	>100 μM Compound: NM 108	Antiviral activity against Vaccinia virus Elstree-Lister infected in african green monkey Vero cells after 3 days by plaque reduction assay Antiviral activity against Vaccinia virus Elstree-Lister infected in african green monkey Vero cells after 3 days by plaque reduction assay	[PMID: 20359898]
Vero	EC₅₀	>100 μM Compound: NM 108	Antiviral activity against HSV1 infected in african green monkey Vero 76 cells assessed as reduction in plaque number after 3 days by plaque reduction assay Antiviral activity against HSV1 infected in african green monkey Vero 76 cells assessed as reduction in plaque number after 3 days by plaque reduction assay	[PMID: 25082514]
Vero	EC₅₀	>100 μM Compound: NM 108	Antiviral activity against Poliovirus type 1 Sabin strain infected in african green monkey Vero 76 cells assessed as reduction in plaque number after 2 days by plaque reduction assay Antiviral activity against Poliovirus type 1 Sabin strain infected in african green monkey Vero 76 cells assessed as reduction in plaque number after 2 days by plaque reduction assay	[PMID: 25082514]
Vero	EC₅₀	>100 μM Compound: NM 108	Antiviral activity against Respiratory syncytial virus infected in african green monkey Vero 76 cells assessed as reduction in plaque number after 5 days by plaque reduction assay Antiviral activity against Respiratory syncytial virus infected in african green monkey Vero 76 cells assessed as reduction in plaque number after 5 days by plaque reduction assay	[PMID: 25082514]
Vero	EC₅₀	>100 μM Compound: NM 108	Antiviral activity against Vaccinia Virus infected in african green monkey Vero 76 cells assessed as reduction in plaque number after 3 days by plaque reduction assay Antiviral activity against Vaccinia Virus infected in african green monkey Vero 76 cells assessed as reduction in plaque number after 3 days by plaque reduction assay	[PMID: 25082514]
Vero	EC₅₀	>100 μM Compound: NM 108	Antiviral activity against Vesicular stomatitis virus infected in african green monkey Vero 76 cells assessed as reduction in plaque number after 2 days by plaque reduction assay Antiviral activity against Vesicular stomatitis virus infected in african green monkey Vero 76 cells assessed as reduction in plaque number after 2 days by plaque reduction assay	[PMID: 25082514]
Vero	EC₅₀	20 μM Compound: NM 108	Antiviral activity against Human coxsackievirus B2 Ohio-1 infected in african green monkey Vero cells after 3 days by plaque reduction assay Antiviral activity against Human coxsackievirus B2 Ohio-1 infected in african green monkey Vero cells after 3 days by plaque reduction assay	[PMID: 20359898]
Vero	EC₅₀	20 μM Compound: NM 108	Antiviral activity against Coxsackievirus B5 infected in african green monkey Vero 76 cells assessed as reduction in plaque number after 3 days by plaque reduction assay Antiviral activity against Coxsackievirus B5 infected in african green monkey Vero 76 cells assessed as reduction in plaque number after 3 days by plaque reduction assay	[PMID: 25082514]
Vero 76	CC₅₀	>100 μM Compound: NM 108	Cytotoxicity against mock-infected african green monkey Vero 76 cells after 48 to 96 hrs by MTT assay Cytotoxicity against mock-infected african green monkey Vero 76 cells after 48 to 96 hrs by MTT assay	[PMID: 25082514]
Vero 76	CC₅₀	>100 μM Compound: NM108	Cytotoxicity against african green monkey Vero 76 cells assessed as cell viability after 48 to 96 hrs by crystal violet staining method Cytotoxicity against african green monkey Vero 76 cells assessed as cell viability after 48 to 96 hrs by crystal violet staining method	[PMID: 26443549]
Vero 76	EC₅₀	>100 μM Compound: NM 108	Antiviral activity against HSV1 infected in Vero-76 cells after 3 days by plaque reduction assay Antiviral activity against HSV1 infected in Vero-76 cells after 3 days by plaque reduction assay	[PMID: 19482481]
Vero 76	EC₅₀	>100 μM Compound: NM 108	Antiviral activity against Respiratory syncytial virus A2 infected in Vero-76 cells after 5 days by plaque reduction assay Antiviral activity against Respiratory syncytial virus A2 infected in Vero-76 cells after 5 days by plaque reduction assay	[PMID: 19482481]
Vero 76	EC₅₀	>100 μM Compound: NM108	Antiviral activity against Human poliovirus 1 Sabin infected in african green monkey Vero76 cells assessed as inhibition of virus-induced cytopathogenicity by plaque reduction assay Antiviral activity against Human poliovirus 1 Sabin infected in african green monkey Vero76 cells assessed as inhibition of virus-induced cytopathogenicity by plaque reduction assay	[PMID: 26443549]
Vero 76	EC₅₀	>100 μM Compound: NM108	Antiviral activity against human RSV infected in african green monkey Vero76 cells assessed as inhibition of virus-induced cytopathogenicity after 5 days by plaque reduction assay Antiviral activity against human RSV infected in african green monkey Vero76 cells assessed as inhibition of virus-induced cytopathogenicity after 5 days by plaque reduction assay	[PMID: 26443549]
Vero 76	EC₅₀	>100 μM Compound: NM-108	Antiviral activity against RSV infected in Vero76 cells assessed as reduction in virus plaque formation after 4 days by MTT assay Antiviral activity against RSV infected in Vero76 cells assessed as reduction in virus plaque formation after 4 days by MTT assay	[PMID: 18760610]
Vero 76	EC₅₀	>100 μM Compound: NM-108	Antiviral activity against Sb1 virus infected in Vero76 cells assessed as reduction in virus plaque formation after 4 days by MTT assay Antiviral activity against Sb1 virus infected in Vero76 cells assessed as reduction in virus plaque formation after 4 days by MTT assay	[PMID: 18760610]
Vero 76	EC₅₀	20 μM Compound: NM 108	Antiviral activity against Coxsackie virus type B2 virus infected in african green monkey Vero-76 cells after 3 days by plaque reduction assay Antiviral activity against Coxsackie virus type B2 virus infected in african green monkey Vero-76 cells after 3 days by plaque reduction assay	[PMID: 19482481]
Vero 76	EC₅₀	20 μM Compound: NM108	Antiviral activity against human CVB5 infected in african green monkey Vero76 cells assessed as inhibition of virus-induced cytopathogenicity after 3 days by plaque reduction assay Antiviral activity against human CVB5 infected in african green monkey Vero76 cells assessed as inhibition of virus-induced cytopathogenicity after 3 days by plaque reduction assay	[PMID: 26443549]
Vero 76	EC₅₀	20 μM Compound: NM-108	Antiviral activity against CVB2 infected in Vero76 cells assessed as reduction in virus plaque formation after 4 days by MTT assay Antiviral activity against CVB2 infected in Vero76 cells assessed as reduction in virus plaque formation after 4 days by MTT assay	[PMID: 18760610]

Chemical Information

CAS No. 374750-30-8
Appearance Solid
Molecular Weight 297.27
Formula C₁₁H₁₅N₅O₅
Color White to off-white
SMILES

O[C@H]1[C@](O)(C)[C@H](N2C=NC3=C2N=C(NC3=O)N)O[C@@H]1CO
Synonyms

2'-C-beta-Methylguanosine
Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
In solvent	-80°C	6 months
	-20°C	1 month

Purity & Documentation

Select Batch:

Purity: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (269 KB)
SDS (419 KB)
- English - EN (419 KB)
- Français - FR (419 KB)
- Deutsch - DE (419 KB)
- Norwegian - NO (419 KB)
- Español - ES (419 KB)
- Swedish - SV (419 KB)
- Italian - IT (419 KB)
- Portuguese - PT (419 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

References

[1]. Lee J, et al. Molecular basis for the immunostimulatory activity of guanine nucleoside analogs: activation of Toll-like receptor 7. Proc Natl Acad Sci U S A. 2003 May 27;100(11):6646-51. [Content Brief]

Calculators

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Dilution Calculator

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Keywords

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Product Name:
CAS No.:
Species:
Purity:
Quantity:

2'-C-Methylguanosine

Cell Cycle/DNA Damage Compound Library

Antiviral Compound Library

Anti-Aging Compound Library

Reprogramming Compound Library

Nucleotide Compound Library

Anti-Lung Cancer Compound Library

Anti-Blood Cancer Compound Library

Anti-Cancer Metabolism Compound Library

Human Metabolite Library

Anti-Hematopathy Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Bioactive Compound Library

High-Throughput Bioactive Compound Library

Mass Spectrometry Human Metabolite Library

Biological Activity

Chemical Information

Purity & Documentation

References

Calculators

Help & FAQs

2'-C-Methylguanosine

Cell Cycle/DNA Damage Compound Library

Antiviral Compound Library

Anti-Aging Compound Library

Reprogramming Compound Library

Nucleotide Compound Library

Anti-Lung Cancer Compound Library

Anti-Blood Cancer Compound Library

Anti-Cancer Metabolism Compound Library

Human Metabolite Library

Anti-Hematopathy Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Bioactive Compound Library

High-Throughput Bioactive Compound Library

Mass Spectrometry Human Metabolite Library

Biological Activity

Chemical Information

Purity & Documentation

References

Calculators

Help & FAQs

2'-C-Methylguanosine Related Classifications

Cat. No.: HY-128139